SEARCH

SEARCH BY CITATION

References

  • 1
    Miyamoto T, Ogino N, Yamamoto S, Hayaishi O. Purification of prostaglandin synthetase from bovine vesicular gland microsomes. Journal of Biological Chemistry 1976; 251: 2629 36.
  • 2
    Smith WL. Prostanoid biosynthesis and mechanisms of action. American Journal of Physiology 1992; 263: F181 91.
  • 3
    Simmons DL, Levy DB, Yannoni Y, Erikson RL. Identification of a phorbol ester-repressible v-rsc-inducible gene. Proceedings of National Academy of Sciences, USA 1989; 86: 1178 82.
  • 4
    Flower RJ & Vane JR. Inhibition of prostaglandin synthetase in brain explains the antipyretic activity of paracetamol (4-acetamidophenol). Nature 1972; 240: 410 1.
  • 5
    Vane JR & Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. American Journal of Medicine 1998; 104: 2S 8S.
  • 6
    Williams CS & DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? American Journal of Physiology 1996; 270: G393 400.
  • 7
    Picot D, Loll PJ, Gravito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994; 367: 243 9.
  • 8
    Smith WL & DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Seminars in Nephrology 1995; 15: 179 94.
  • 9
    Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. American Journal of Physiology 1983; 245: G601 23.
  • 10
    Watson AJ. Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. Histology and Histopathology 1998; 13: 591 7.
  • 11
    Schneider A & Stahl RAK. Cyclo-oxygenase-2 (COX-2) and the kidney: current status and potential perspectives. Nephrology, Dialysis and Transplantation 1998; 13: 10 2.
  • 12
    Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. American Journal of Physiology 1998; 274: R263 79.
  • 13
    Venturini CM, Isakson P, Needleman P. Non-steroidal anti-inflammatory drug-induced renal failure: a brief review of the role of cyclo-oxygenase isoforms. Current Opinion in Nephrology and Hypertension 1998; 7: 79 82.
  • 14
    Morham SG, Lagenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473 82.
  • 15
    Hayashi O. Molecular mechanisms of sleep-awake regulation: roles of prostaglandin D2 and E2. FASEB Journal 1991; 5: 2575 81.
  • 16
    Peri KG, Hardy P, Li DY, Varma DR, Chemtob S. Prostaglandin G/H synthase-2 is a major contributor to brain prostaglandins in the newborn. Journal of Biological Chemistry 1995; 270: 24615 20.
  • 17
    Yamagata K, Andreasson KI, Kaufman WE, Barnes CA, Worsley PF. Expression of a mitogen-inducible cyclo-oxygenase in brain neurons; regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371 86.
  • 18
    Marcheselli VL & Bazan NG. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Journal of Biological Chemistry 1996; 271: 24794 9.
  • 19
    Cao C, Matsumara K, Yamagata K, Watanabe Y. Endothelial cells of the brain vasculature express cyclo-oxygenase-2 mRNA in response to systemic interleukin-1B: a possible site of prostaglandin synthesis responsible for fever. Brain Research 1996; 733: 263 72.
  • 20
    Osuka K, Suzuki Y, Watanabe Y, Takayasu M, Yoshida J. Inducible cyclo-oxygenase expression in canine basilar artery after experimental subarachnoid hemorrhage. Stroke 1998; 29: 1219 922.
  • 21
    Yamamoto T & Nozaki-Taguchi N. Analysis of the effects of cyclo-oxygenase (COX) -1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor. Brain Research 1996; 739: 104 10.
  • 22
    Okazaki T, Casey MI, Okita JR, Macdonald PC, Johnson JM. Initiation of human parturition XII. Biosynthesis and metabolism of prostaglandins in human fetal membranes and uterine decidua. American Journal of Obstetrics and Gynecology 1981; 139: 373 81.
  • 23
    Trautman MS, Edwin SS, Collmer D, Dudley DJ, Simmons D, Mitchell MD. Prostaglandin H synthase-2 in human gestational tissues: Regulation in amnion. Placenta 1996; 17: 239 45.
  • 24
    Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclo-oxygenase II. Nature 1995; 378: 406 9.
  • 25
    Hempel SL, Monick MM, Huninghake GW. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. Journal of Clinical Investigation 1994; 93: 391 6.
  • 26
    Creminon C, Habib A, Maclouf J, Pradelles P, Grassi J, Frobert Y. Differential measurement of constitutive (COX-1) and inducible (COX-2) cyclo-oxygenase expression in human umbilical vein endothelial cells using immunometric enzyme immunoassays. Bichimica et Biophysica Acta 1995; 1254: 341 8.
  • 27
    Hla T, Ristimaki A, Appleby S, Barriocanal JG. Cyclo-oxygenase gene expression in inflammation and angiogenesis. Annals of the New York Academy of Sciences 1993; 696: 197 204.
  • 28
    Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclo-oxygenase-1 ans-2 expression in rheumatoid synovial tissues. Journal of Clinical Investigation 1994; 93: 1095 101.
  • 29
    Pavord ID & Tattersfield AE. Bronchoprotective role for endogenous prostaglandin E sub 2. Lancet 1995; 345: 436 8.
  • 30
    Mitchell JA & Belvisi MG. Too many COX (cyclo-oxygenase) spoil the broth: aspirin −sensitive asthma and 5-lipoxygenase. Thorax 1997; 52: 933 5.
  • 31
    Maclouf J, Folco G, Patrono C. Eicosanoids and Iso-eicosanoids; constitutive, inducible and transcellular biosynthesis in vascular disease. Thrombosis Hemostasis 1998; 79: 691 705.
  • 32
    Hawkey CJ. The Gastroenterologist's caseload: contribution of the rheumatologist. Seminars in Arthritis and Rheumatology 1997; 26: 11 5.
  • 33
    Solomon DH & Gurwitz JH. Toxicity of nonsteroidal antiinflammatory drugs in the elderly; is advanced age a risk factor? American Journal of Medicine 1997; 102: 208 15.
  • 34
    Sousa AR, Pfister R, Christie PE, et al. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic subjects and its cellular distribution in aspirin sensitive asthma. Thorax 1997; 52: 940 5.
  • 35
    Ruoff GE. The impact of non-steroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clinical Therapeutics 1998; 20: 376 87.
  • 36
    Menahem S. Prostaglandin inhibitors during pregnancy and the effect on the fetus. Australian and New Zealand Journal of Obstetrics and Gynaecology 1991; 31: 190 1.
  • 37
    Forwood MR. Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. Journal of Bone and Mineral Research 1996; 11: 1688 93.
  • 38
    Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterisation of the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. Journal of Pharmacolgy and Experimental Therapeutics 1994; 271: 1705 10.
  • 39
    Frolich JC. A classification of NSAIDs according to the relative inhibition of cyclo-oxygenase isoenzymes. Trends in Pharmacological Sciences 1997; 18: 30 4.
  • 40
    Masteferrer Jl, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclo-oxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proceedings of National Academy of Sciences, USA 1994; 91: 3228 32.
  • 41
    Lane NE. Pain Management in Osteoarthritis: The role of COX-2 inhibitors. Journal of Rheumatology Supplement 1997; 49: 20 4.
  • 42
    Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclo-oxygenase 2 inhibitor. Arthritis Rheumatism 1998; 41: 1591 602.
  • 43
    Mengle-Gaw L, Hubbard RC, Karim A, et al. A study of platelet effects of SC-58635, a novel COX-2 selective inhibitor. Arthritis Rheumatism 1997; 40 (Suppl. 9): S93.
  • 44
    Chan CC, Gordon R, Brideau C, et al. In vivo pharmacology of L-745,337: a novel non-steroidal antiinflammatory agent (NSAID) with an ulcerogenic sparing effect in rat and monkey stomach. Canadian Journal of Physiology and Pharmacology 1994; 72 (Suppl. 1): 266.
  • 45
    Hirschelmann R, Hentschel M, Geissler J, Rickinger O. CGP 28238, a new potent nonsteroidal antiinflammatory agent: Its relation to arachidonic acid metabolism. Agents Actions 1991; 32: 54 5.
  • 46
    Vane JR, Bjarnason I, Fenner H. Meloxicam. Drugs 1996; 51: 431 2.
  • 47
    Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group; Meloxicam Large-scale International Study Safety Assessment. British Journal of Rheumatology 1998; 37: 937 45.
  • 48
    Tegedrer I, Lotsch J, Krebs S, Muth-Selbach U, Brune K, Geisslinger G. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clinical Pharmacology and Therapeutics 1999; 65: 533 44.
  • 49
    Saag K, Fisher C, Mckay J, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis in a six week controlled clinical trial. Arthritis Rheumatism 1998; 41 (Suppl. 9): S196.
  • 50
    Cryer B, Gottesdiener MD, Gertz B, Hsieh P, Dallob A, Feldman M. Effects of a novel cyclo-oxygenase (COX) -2 inhibitor on gastric mucosal prostaglandin (PG) synthesis in healthy humans. American Journal of Gastroenterology 1998; 93: A104.